5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis

Table 1 Demographic and clinical characteristics of patients

Characteristics	pH-dependent delayed release (n= 73)	Pro-drugs (n= 18)	Time-dependent sustained release (n= 11)
Age (mean ± SE) (yr)	47.24 ± 1.61	51.38 ± 2.39	47.54 ± 4.97
Gender (M/F)	49/24	8/10	6/5
Extent of disease
Proctosigmoiditis	22%	22%	0%
Left colitis	10%	11%	0%
Pancolitis	68%	67%	100%
Age at diagnosis (mean ± SE)	34.88 ± 1.61	32.72 ± 2.30	31.09 ± 3.30
Duration of disease (yr)	11.56 ± 0.81	17.22 ± 4.21	15.00 ± 2.62
Time since last 5-ASA administration (h)	21.43 ± 1.22	23.88 ± 4.21	20.63 ± 2.52

M: Male; F: Female; 5-ASA: 5-aminosalicylic acid.